Microbiological stability tests with simulated broth preparations and integrity testing for sterile standard cytotoxic preparations

Abstract

ObjectivesThe objectives were to assess the microbiological stability and the physical enclosure integrity of the overwrapping for batch production of standard cytotoxic injectable solutions.MethodsBroth culture media were used in place of cytotoxic drugs to assess the worst case in term of microbiological contamination risk. Iterative sterility tests on batches were performed for 60 days using rapid microbiological method. Validation of microbiological growth of culture media was assessed by direct inoculation of <100 CFU/mL of six microbiological strains recommended by European Pharmacopeia. Validation of the ability of growth of microorganisms in 11 cytotoxic solutions and one monoclonal antibody was assessed using eight strains. In addition, the physical integrity of the seal of the overwrapping containing cytotoxic preparations was assessed by dynamometric method and dye penetration test.ResultsNo microbiological contamination was observed on all units of batches for 60 days of investigation. The ability to detect microbiological growth in cytotoxic solutions was validated for the eight challenge microorganisms after 1/10 dilution for cytotoxic investigated, except for 5 Fluorouracil, gemcitabine and cisplatin. In addition, physical integrity testing of the seal of overwrapping pointed out the need of specific validation of heatsealer and operator education.ConclusionsBesides physico-chemical testing, microbiological stability testing combined to physical integrity testing is the additional part of the development method for batch production of sterile drugs in hospital.

Viability of selected microorganisms in parenteral preparations for novel systemic anti-cancer therapy

“…Several studies regarding the potential of microbial growth in cytotoxic and non-cytotoxic RTA parenteral preparations have been published. 4,[7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] Viability tests are missing for numerous recently licensed monoclonal antibodies (mAb), filgrastim, and few small molecules introduced in anti-cancer therapy in recent years. The aim of this viability study was to investigate the potential growth promoting nature of 20 RTA parenteral preparations used for SACT.…”